Skip to main content

Table 3 Association of quartiles of inflammatory markers measured at Tanner 2 and Tanner 4 with breast composition measured at Tanner 4

From: Association between indicators of systemic inflammation biomarkers during puberty with breast density and onset of menarche

Inflammatory marker

Breast Tanner stage

 

Relative change in breast composition compared to Q1 (95% CI)F

 

N

LRT p valueD

Q2

Q3

Q4

p for TrendE

Age-adjusted modelA

 Total breast volume

  CRP

Tanner 2

246

0.054

1.20 (1.03–1.41)*

1.14 (0.98–1.32)

1.19 (1.02–1.38)*

0.037

Tanner 4

343

0.199

1.15 (0.99–1.33)

1.10 (0.97–1.26)

1.11 (0.98–1.26)

0.131

  IL-6

Tanner 2

272

0.036

1.13 (0.98–1.31)

1.19 (1.03–1.37)*

1.22 (1.05–1.42)*

0.010

Tanner 4

341

< 0.0001

1.23 (1.08–1.40)**

1.27 (1.11–1.45)***

1.41 (1.24–1.61)***

< 0.0001

  TNFR2

Tanner 2

272

0.001

1.02 (0.88–1.18)

1.23 (1.06–1.42)**

1.26 (1.09–1.47)**

< 0.001

Tanner 4

341

0.002

1.18 (1.03–1.35)*

1.24 (1.08–1.42)**

1.29 (1.12–1.48)***

< 0.001

 Fibroglandular volume

  CRP

Tanner 2

246

0.759

1.07 (0.94–1.24)

1.04 (0.91–1.19)

1.01 (0.89–1.16)

0.840

Tanner 4

343

0.161

0.99 (0.87–1.13)

0.99 (0.88–1.11)

0.89 (0.80–0.99)*

0.066

  IL-6

Tanner 2

272

0.687

0.98 (0.86–1.12)

0.96 (0.85–1.09)

1.05 (0.92–1.20)

0.536

Tanner 4

341

0.156

1.03 (0.91–1.16)

0.89 (0.79–1.01)

0.99 (0.88–1.11)

0.432

  TNFR2

Tanner 2

272

0.466

0.98 (0.86–1.11)

1.08 (0.95–1.23)

0.98 (0.86–1.12)

0.883

Tanner 4

341

0.585

1.06 (0.94–1.20)

1.09 (0.96–1.23)

1.06 (0.93–1.20)

0.380

 Percent fibroglandular volume

  CRP

Tanner 2

246

0.082

0.89 (0.78–1.02)

0.92 (0.81–1.04)

0.86 (0.76–0.97)*

0.023

Tanner 4

343

0.001

0.87 (0.76–0.99)*

0.90 (0.80–1.01)

0.80 (0.72–0.90)***

< 0.001

  IL-6

Tanner 2

272

0.005

0.86 (0.76–0.98)*

0.81 (0.72–0.92)***

0.86 (0.76–0.98)*

0.018

Tanner 4

341

< 0.0001

0.84 (0.75–0.94)**

0.71 (0.63–0.79)***

0.70 (0.63–0.78)***

< 0.0001

  TNFR2

Tanner 2

272

< 0.001

0.96 (0.85–1.09)

0.88 (0.77–0.99)*

0.78 (0.69–0.89)***

< 0.0001

Tanner 4

341

0.017

0.91 (0.80–1.02)

0.88 (0.78–0.99)*

0.82 (0.72–0.93)**

0.002

Age and body fatness-adjusted modelB

 Total breast volume

  CRP

Tanner 2

245

0.242

1.13 (1.00–1.29)

1.09 (0.96–1.23)

1.07 (0.95–1.22)

0.272

Tanner 4

343

0.043

1.02 (0.92–1.14)

1.02 (0.93–1.12)

0.90 (0.82–0.99)*

0.077

  IL-6

Tanner 2

271

0.986

1.01 (0.90–1.14)

1.02 (0.90–1.15)

1.00 (0.88–1.14)

0.991

Tanner 4

341

0.191

1.09 (0.99–1.20)

0.98 (0.88–1.09)

1.04 (0.93–1.15)

0.906

  TNFR2

Tanner 2

271

0.344

1.00 (0.89–1.12)

1.10 (0.97–1.24)

1.06 (0.93–1.20)

0.211

Tanner 4

341

0.030

1.14 (1.03–1.25)*

1.14 (1.03–1.26)*

1.06 (0.96–1.18)

0.297

 Fibroglandular volume

  CRP

Tanner 2

245

0.775

1.07 (0.93–1.24)

1.04 (0.91–1.19)

1.01 (0.88–1.16)

0.884

Tanner 4

343

0.146

0.99 (0.87–1.12)

0.99 (0.88–1.11)

0.88 (0.79–0.99)*

0.060

  IL-6

Tanner 2

271

0.694

0.98 (0.86–1.12)

0.96 (0.84–1.10)

1.05 (0.91–1.21)

0.540

Tanner 4

341

0.161

1.02 (0.91–1.16)

0.89 (0.78–1.01)

0.98 (0.87–1.12)

0.465

  TNFR2

Tanner 2

271

0.478

0.98 (0.86–1.11)

1.08 (0.94–1.23)

0.98 (0.85–1.13)

0.915

Tanner 4

341

0.563

1.07 (0.94–1.20)

1.09 (0.96–1.24)

1.06 (0.94–1.21)

0.336

 Percent fibroglandular volume

  CRP

Tanner 2

245

0.535

0.94 (0.86–1.04)

0.95 (0.87–1.05)

0.94 (0.86–1.04)

0.227

Tanner 4

343

0.750

0.97 (0.89–1.05)

0.96 (0.90–1.04)

0.98 (0.91–1.05)

0.448

  IL-6

Tanner 2

271

0.169

0.97 (0.88–1.06)

0.94 (0.86–1.04)

1.05 (0.95–1.16)

0.347

Tanner 4

341

0.126

0.94 (0.87–1.01)

0.91 (0.84–0.98)*

0.95 (0.88–1.02)

0.169

  TNFR2

Tanner 2

271

0.487

0.99 (0.90–1.08)

0.98 (0.89–1.08)

0.93 (0.84–1.02)

0.151

Tanner 4

341

0.260

0.94 (0.87–1.01)

0.96 (0.89–1.03)

1.00 (0.92–1.08)

0.874

Multivariable-adjusted modelC

 Total breast volume

  CRP

Tanner 2

236

0.314

1.12 (0.98–1.28)

1.08 (0.96–1.23)

1.08 (0.95–1.22)

0.234

Tanner 4

332

0.247

1.03 (0.93–1.14)

1.02 (0.93–1.12)

0.94 (0.85–1.03)

0.286

  IL-6

Tanner 2

262

0.951

1.01 (0.90–1.14)

1.03 (0.91–1.16)

1.00 (0.88–1.13)

0.983

Tanner 4

330

0.096

1.11 (1.01–1.23)*

0.99 (0.89–1.10)

1.05 (0.95–1.17)

0.713

  TNFR2

Tanner 2

262

0.132

0.99 (0.88–1.12)

1.13 (1.00–1.27)

1.08 (0.95–1.22)

0.097

Tanner 4

330

0.036

1.12 (1.01–1.23)*

1.14 (1.03–1.27)*

1.04 (0.94–1.16)

0.468

 Fibroglandular volume

  CRP

Tanner 2

236

0.787

1.07 (0.93–1.23)

1.05 (0.92–1.20)

1.03 (0.90–1.18)

0.695

Tanner 4

332

0.556

0.99 (0.88–1.13)

0.99 (0.88–1.11)

0.92 (0.82–1.04)

0.236

  IL-6

Tanner 2

262

0.671

0.99 (0.86–1.13)

0.97 (0.85–1.11)

1.06 (0.92–1.22)

0.429

Tanner 4

330

0.139

1.05 (0.93–1.18)

0.90 (0.79–1.03)

1.01 (0.89–1.14)

0.650

  TNFR2

Tanner 2

262

0.347

0.99 (0.87–1.13)

1.11 (0.97–1.27)

1.00 (0.87–1.15)

0.617

Tanner 4

330

0.599

1.04 (0.92–1.18)

1.09 (0.96–1.24)

1.03 (0.91–1.17)

0.600

 Percent fibroglandular volume

  CRP

Tanner 2

236

0.721

0.96 (0.87–1.06)

0.97 (0.88–1.07)

0.95 (0.87–1.05)

0.340

Tanner 4

332

0.769

0.97 (0.89–1.05)

0.96 (0.90–1.04)

0.98 (0.91–1.06)

0.579

  IL-6

Tanner 2

262

0.105

0.97 (0.88–1.07)

0.94 (0.86–1.04)

1.07 (0.96–1.18)

0.236

Tanner 4

330

0.134

0.94 (0.87–1.02)

0.91 (0.84–0.99)*

0.95 (0.88–1.03)

0.226

  TNFR2

Tanner 2

262

0.486

1.00 (0.91–1.10)

0.98 (0.89–1.08)

0.93 (0.84–1.03)

0.166

Tanner 4

330

0.296

0.93 (0.86–1.01)

0.95 (0.88–1.03)

0.98 (0.91–1.07)

0.893

  1. ALinear regression model adjusting for age at inflammatory biomarker measurement
  2. BModel adjusting for age at inflammatory biomarker measurement and fat percentage at biomarker measurement
  3. CModel adjusting for age at inflammatory biomarker measurement, fat percentage at biomarker measurement, ethnicity, birth weight, height age- and sex-specific Z-score, and maternal education
  4. DLikelihood ratio test (LRT) p value for whether the addition of inflammatory biomarker quartiles improved model fit relative to the model without indicators for inflammatory biomarker quartiles
  5. EWald test p value for log-transformed median within each quartile included as a continuous covariate in models adjusting for age at inflammatory biomarker measurement, fat percentage at biomarker measurement, ethnicity, birth weight, height age- and sex-specific Z-score, and maternal education
  6. FInflammatory marker quartiles at Tanner 2: CRP (mg/L) [0.1–0.3], [0.4–0.7], [0.8–2.2], [2.3–15.7]; IL-6 (pg/mL) [0.3–0.8], [0.9–1.3], [1.4–2.2], [2.3–30.4]; TNFR2 (pg/mL) [944.4–1894.1], [1897.2–2169.0], [2171.9–2533.7], [2545.9–4902.5]. Inflammatory marker quartiles at Tanner 4: CRP (mg/L) [0.1–0.2], [0.2–0.5], [0.5–1.9], [2.0–18.9]; IL-6 (pg/mL) [0.3–0.8], [0.9–1.3], [1.4–2.1], [2.2–24.0]; TNFR2 (pg/mL) [1106.7–1960.4], [1971.3–2271.1], [2275.8–2638.1], [2639.9–4753.3]
  7. *p < 0.05
  8. **p < 0.01
  9. ***p < 0.001
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us